ID: ALA1077831

Max Phase: Preclinical

Molecular Formula: C30H27F7N4O5S

Molecular Weight: 688.62

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCS(=O)(=O)CCN(C(=O)Cc1ccc(F)c(C(F)(F)F)c1)[C@H](C)c1nc2ncccc2c(=O)n1-c1ccc(OCC(F)(F)F)cc1

Standard InChI:  InChI=1S/C30H27F7N4O5S/c1-3-47(44,45)14-13-40(25(42)16-19-6-11-24(31)23(15-19)30(35,36)37)18(2)27-39-26-22(5-4-12-38-26)28(43)41(27)20-7-9-21(10-8-20)46-17-29(32,33)34/h4-12,15,18H,3,13-14,16-17H2,1-2H3/t18-/m1/s1

Standard InChI Key:  KKZXIEYKPIMYPS-GOSISDBHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 688.62

Molecular Weight (Monoisotopic): 688.1590

AlogP: 5.45

#Rotatable Bonds: 11

Polar Surface Area: 111.46

Molecular Species: NEUTRAL

HBA: 8

HBD: 0

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 0.75

CX LogP: 4.56

CX LogD: 4.56

Aromatic Rings: 4

Heavy Atoms: 47

QED Weighted: 0.19

Np Likeness Score: -1.50

References

1. Liu J, Fu Z, Li AR, Johnson M, Zhu L, Marcus A, Danao J, Sullivan T, Tonn G, Collins T, Medina J..  (2009)  Optimization of a series of quinazolinone-derived antagonists of CXCR3.,  19  (17): [PMID:19632842] [10.1016/j.bmcl.2009.07.032]

Source

Source(1):

• Scientific Literature